Information Provided By: 
Fly News Breaks for October 9, 2017
ELGX
Oct 9, 2017 | 07:47 EDT
Canaccord analyst Jason Mills believes the run in Endologix shares following the FDA approval of the NELLIX confirmatory study is "egregiously overdone" and as a result investors should take profits. Mills, who remains cautious about the company's ability to gain market share in a highly competitive and mature market, maintained his Hold rating and $5.00 price target on Endologix shares.
News For ELGX From the Last 2 Days
There are no results for your query ELGX
